Abstract
Psoriasis can involve the skin, joints, nails and cardiovascular system and result in a significant impairment in quality of life. Studies have shown a lower response rate to systemic anti-sporiatic therapies in smokers, and smoking is a trigger factor for psoriasis. The aim of this study was therefore to analyse the response to systemic therapies for psoriasis, with a focus on smoking. Prospectively collected data from patients with moderate to severe psoriasis included in the national psoriasis registries for Germany and Switzerland (Pso-Best and SDNTT) were analysed. Therapy response was defined as reaching a Psoriasis Area and Severity Index (PASI) reduction of 75%, PASI ≤ 3 or Dermatology Life Quality Index (DLQI) ≤ 1. Out of 5,346 patients included in these registries, 1,264 met the inclusion criteria for this study. In the smoking group, 715 (60.6%) reached therapy response at month 3, compared with 358 (63.7%) in the non-smoking group (p ≤ 0.269), 659 (74.1%) vs. 330 (77%) reached therapy response at month 6 (p ≤ 0.097), and 504 (76.6%) vs. 272 (79.0%) at month 12 (p ≤ 0.611). Therefore, these data do not show that smoking affects the response rate of anti-psoriatic therapy after 3, 6 and 12 months.
| Original language | English |
|---|---|
| Journal | Acta Dermato-Venereologica |
| Volume | 99 |
| Issue number | 10 |
| Pages (from-to) | 871-877 |
| Number of pages | 7 |
| ISSN | 0001-5555 |
| DOIs | |
| Publication status | Published - 2019 |
Funding
The registries are supported by AbbVie, Amgen, Almirall, Biogen, Celgene, Hexal, Janssen-Cilag, LEO Pharma, Eli Lilly, Medac, Novartis and Pfizer. These companies do not have any influence on the design of the register, data collection and analyses, or on publication decisions or manuscript preparation. Conflicts of interest: FA is funded by “Forschungskredit” a competitive grant from the University of Zurich. He has received honoraria from Abbvie, Celgene, Leo Pharma, Galderma and Novartis, but has no financial interest, nor holds any shares in any pharmaceutical company. AAN is funded by the Promedica and Bruno-Bloch Foundation. MA has received research grants and/ or consulting or lecturing fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Hexal, Janssen-Cilag, Leo, Medac, MSD, Mundipharma, No-vartis, Pfizer, Sandoz and Xenoport. MAR has received research grants and/or consulting or lecturing fees from Abbvie, Almirall, Amgen, Astellas, Biogen, Biologix, Böhringer, Celgene, Eli Lilly, Galderma, Hexal, Janssen-Cilag, La Roche Posay, Leo, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, Sanofi. NY has received honoraria for consulting and advisory board attendance from Abbvie, Almirall, Amgen, Celgene, Eli Lilly, Galderma, Janssen, Leo, Novartis, MSD and Pfizer. KR has served as advisor and/or paid speaker for and/or participated in clinical trials sponsored by Abbvie, Affibody, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Kyowa Ki-rin, Leo, Lilly, Medac, Merck Sharp & Dohme, Novartis, Ocean Pharma, Pfizer, Regeneron, Samsung Bioepis, Sanofi, Takeda, UCB, Valeant, Xenoport. CS is an employee of UKE. LEF has received honoraria for consulting and advisory board attendance from Abbvie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, Leo, Novartis, and Pfizer. UM has been an advisor and/or received speaker’s honoraria and/or received grants and/or participated in clinical trials of the following companies: AbbVie, Almirall, Amgen, Biogen, Boehringer-Ingelheim, Celgene, Dr Reddy’s, Eli Lilly, Foamix, Formycon, Forward Pharma, Janssen, Leo Pharma, Medac, MSD, Novartis, UCB, VBL and Xenoport. J-TM is an employee of USZ and holds a “Filling the GAP” scholarship. AAN is funded by the Promedica and Bruno-Bloch Foundation. He is also on the advisory board of Galderma. All other authors have no conflicts of interest to declare.
Research Areas and Centers
- Academic Focus: Center for Infection and Inflammation Research (ZIEL)
